Failures at the clinical stage can be prevented using translational models

‍

► Clinical trials with JNJ-61610588, a VISTA-targeting compound, were suspended due to CRS-related side effects missed by the preclinical model used.

► These side effects could have been predicted if the genO-BRGSF-HIS model had been used at the preclinical stage.

‍

Cytokine release in genO-BRGSF-HIS mice treated with JNJ-61610588

‍

Data adapted from Martin et al., Front Immunol, 2024

genO‑BRGSF‑HIS accurately predicted Sensei Bio’s anti-VISTA antibody clinical outcomes

‍

► Following the toxicity issues with JNJ-61610588, Sensei Bio developed a new anti-VISTA compound, SNS-101, which safety was successfully tested in genO‑BRGSF‑HIS mice.

‍

Cytokine release in genO-BRGSF-HIS mice treated with SNS-101

‍

‍

► In clinical trials, SNS-101 mirrored the results seen in genO‑BRGSF‑HIS mice, corroborating the model's translatability.

Preliminary safety clinical results with SNS-101

‍

‍

Adapted from Sen et al., Sensei Bio's poster presented at SITC 2023

What sets the genO-BRGSF-HIS mouse model apart?

Key features:

Functional human myeloid and lymphoid compartments upon CD34+ HSC-reconstitution
Dynamic recruitment of immune cells into the TME and activation profile shaped by tumor burden and type
Reduced number of murine myeloid cells
Resistance to irradiation
Highly permissive to PDX and CDX engraftment
Presence of functional γδ T cells
Long lifespan and stable immune system engraftment enabling assessment of compounds with large therapeutic window